CLICK HERE FOR A RECENT IMPORTANT SAFETY UPDATE TO UBRELVY^®

FOR A RECENT IMPORTANT SAFETY UPDATE TO UBRELVY FOR A RECENT IMPORTANT SAFETY UPDATE TO UBRELVY FOR A RECENT IMPORTANT SAFETY UPDATE TO UBRELVY CLICK HERE

Request Samples

Request a Rep

Speaker Programs

Request Samples

Request a Rep

Speaker Programs

Pain relief at 2 hours was demonstrated in 62% (UBRELVY 50 mg) vs 49% (placebo) when taken immediately or within 4 hours of onset^3,4

Pain freedom at 2 hours (co-primary endpoint) was demonstrated in 21% (UBRELVY 50 mg) vs 13% (placebo).³ Sustained pain freedom from 2 to 24 hours (secondary endpoint) was achieved in 14% (UBRELVY 50 mg) vs 8% (placebo)¹

UBRELVY has been prescribed over 2 million times by more than 80,000 HCPs, treating over 500,000 patients³

Ubrelvyhcp Hero Banner

ubrelvyhcp stamp.png

Strike down to zero
migraine pain with Ubrelvy^®

RAPID: Quick pain relief¹

Pain relief at 2 hours was demonstrated in 62% (UBRELVY 50 mg) vs 49% (placebo) when taken immediately or within 4 hours of onset^3,4

POWERFUL: Zero pain, sustained^1,3

Pain freedom at 2 hours (co-primary endpoint) was demonstrated in 21% (UBRELVY 50 mg) vs 13% (placebo).³ Sustained pain freedom from 2 to 24 hours (secondary endpoint) was achieved in 14% (UBRELVY 50 mg) vs 8% (placebo)¹

PROVEN: Well established in market³

UBRELVY has been prescribed over 2 million times by more than 80,000 HCPs, treating over 500,000 patients³

Streamline the prescribing process

Get patients started

Once you've decided to prescribe UBRELVY, enable access for your patients with our U-CONCIERGE program and learn how eligible patients may pay as little as $0—all pills, all fills.*

Help enable access

Prescribe the 16 count

16 count is available for your UBRELVY patients

Migraine attacks can be unpredictable.⁵ Prepare your patients with a 16-count package of UBRELVY 100 mg tablets.

View dosing

See the impact of UBRELVY

See the impact of UBRELVY

UBRELVY is part of a powerful migraine pain tool kit.¹

See how it can help

*Patient out-of-pocket costs may vary. Terms and Conditions apply. This offer is only valid for commercially insured patients. Offer not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs.

Request Samples

Request a Rep

Speaker Programs

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Drug Interactions: UBRELVY is contraindicated with concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

Hypersensitivity Reactions: UBRELVY is contraindicated in patients with a history of serious hypersensitivity to ubrogepant or any ingredient of the product. Cases, including anaphylaxis, dyspnea, facial or throat edema, rash, urticaria, and pruritus, have been reported. Hypersensitivity reactions can occur minutes, hours, or days after administration. Most reactions were not serious, and some led to discontinuation. If a serious or severe reaction occurs, discontinue UBRELVY and institute appropriate therapy.

ADVERSE REACTIONS

The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence (3% vs 1% placebo).

DRUG INTERACTIONS

Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure.
Dose modifications are recommended when using the following:
- Moderate or weak CYP3A4 inhibitors and inducers
- BCRP and/or P-gp only inhibitors

DOSAGE AND ADMINISTRATION

The recommended dose is 50 mg or 100 mg taken orally, as needed.
If needed, a second dose may be administered at least 2 hours after the initial dose.
The maximum dose in a 24-hour period is 200 mg. The safety of treating more than 8 migraines in a 30-day period has not been established.
Severe hepatic or severe renal impairment: Recommended dose is 50 mg; if needed, a second 50 mg dose may be taken at least 2 hours after the initial dose.
Avoid use in patients with end-stage renal disease.

INDICATION

UBRELVY^® (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.

Please see full Prescribing Information.

US-UBR-230117

References: 1. UBRELVY. Package insert. Allergan USA, Inc.; 2021. 2. Retail monthly prescription data from IQVIA on a 6-month rolling basis as of 10/22. 3. Data on file. Allergan. 4. Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887-1898. 5. Serrano D, Lipton RB, Scher Al, et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain. 2017:18:101.

IMPORTANT SAFETY INFORMATION

Contraindication

Drug Interactions: UBRELVY is contraindicated with concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

IMPORTANT SAFETY INFORMATION

Contraindication

Drug Interactions: UBRELVY is contraindicated with concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

IMPORTANT SAFETY INFORMATION

Contraindication

Drug Interactions: UBRELVY is contraindicated with concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

IMPORTANT SAFETY INFORMATION

Contraindication

Drug Interactions: UBRELVY is contraindicated with concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Drug Interactions: UBRELVY is contraindicated with concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

Hypersensitivity Reactions: UBRELVY is contraindicated in patients with a history of serious hypersensitivity to ubrogepant or any ingredient of the product. Cases, including anaphylaxis, dyspnea, facial or throat edema, rash, urticaria, and pruritus, have been reported. Hypersensitivity reactions can occur minutes, hours, or days after administration. Most reactions were not serious, and some led to discontinuation. If a serious or severe reaction occurs, discontinue UBRELVY and institute appropriate therapy.

ADVERSE REACTIONS

The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence (3% vs 1% placebo).

DRUG INTERACTIONS

Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure.
Dose modifications are recommended when using the following:
- Moderate or weak CYP3A4 inhibitors and inducers
- BCRP and/or P-gp only inhibitors

DOSAGE AND ADMINISTRATION

The recommended dose is 50 mg or 100 mg taken orally, as needed.
If needed, a second dose may be administered at least 2 hours after the initial dose.
The maximum dose in a 24-hour period is 200 mg. The safety of treating more than 8 migraines in a 30-day period has not been established.
Severe hepatic or severe renal impairment: Recommended dose is 50 mg; if needed, a second 50 mg dose may be taken at least 2 hours after the initial dose.
Avoid use in patients with end-stage renal disease.

INDICATION

UBRELVY^® (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.

Please see full Prescribing Information.

US-UBR-230117